



Life Sciences Bootcamp for In-House Counsel

September 7, 2022 | Mass Bio | Cambridge, MA

Time	Session
12:00 – 12:45 pm	Lunch/Registration
12:45 – 12:50 pm	Welcome & Opening Remarks Douglas Carsten , Partner, Co-Chair, Life Sciences Industry Group, McDermott Will & Emery
12:50 – 1:40 pm	An Industry Under Scrutiny: In-House Compliance and Government Oversight In the face of an active and evolving enforcement environment, life sciences companies continue to find their businesses under the government microscope through the use of familiar tools such as the False Claims Act, the Anti-Kickback Statute, and other laws and regulations. This panel will discuss how your organization can best position itself to tackle these challenges by establishing a strong compliance program based on the most current considerations and guidance. We will also review effective response strategies if, despite your best efforts, your organization becomes the focus of government scrutiny. Laura McLane , Partner, McDermott Will & Emery Dana McSherry , Partner, McDermott Will & Emery Sarah Walters , Partner, McDermott Will & Emery
1:40 -- 2:10 pm	Presentation by LinkSquares and Networking Break
2:10 – 3:00 pm	Evolving Cybersecurity and Data Considerations for Life Sciences Companies As medical devices and other life sciences products become increasingly connected, the risk of a security breach is similarly on the rise. Data and systems breaches are often costly, cause reputational damage, and can significantly impact the safety and effectiveness of devices used by consumers. During this panel, our team of healthcare privacy and cybersecurity lawyers will share the evolving cybersecurity and data considerations — including FDA-specific and healthcare data governance issues — that life sciences companies should heed to mitigate risk and protect their products. Ed Zacharias , Partner, McDermott Will & Emery Robert Duffy , Counsel, McDermott Will & Emery

Life Sciences Bootcamp for In-House Counsel



September 7, 2022 | Cambridge, MA

3:05 – 3:55 pm

FDA Exclusivities & IP Considerations

This cross-disciplinary panel will focus on patent strategy and portfolio development for small and established companies, and the intersection between patent strategy and your technology's FDA/regulatory pathway. Topics will include generics and biosimilars, orphan and special product exclusivities, patentable subject matter, patent term extensions, and trademarks and product naming.

Douglas Carsten, Partner, McDermott Will & Emery

Jenny Chen, Partner, McDermott Will & Emery

Chuck Larsen, Partner, McDermott Will & Emery

Brian Malkin, Partner, McDermott Will & Emery

3:55 – 4:10 pm

Break

4:10 – 5:00 pm

Key M&A Considerations: Pre- and Post-Acquisition

Major transactions are continuing to reshape the industry landscape and capital market trends suggest a potential round of consolidations ahead. This panel of tax and transactional lawyers will discuss how to prepare for M&A activity, and review issues to keep in mind during post-merger integration.

Michael Hardgrove, Partner, McDermott Will & Emery

John Karasek, Counsel, McDermott Will & Emery

Richard Smith, Counsel, McDermott Will & Emery

5:00 – 6:00 pm

Networking Reception